Array BioPharma Inc. (NASDAQ:ARRY) currently has a “Buy” signals on Composite indicators by TrendSpotter. While the Short-Term Technical Indicators for the stock on 7-Day Average Directional Indicator shows “Buy” signal. 10 – 8 Day Moving Average Hilo Channel shows “Buy” signal. While 20-Day Moving Average VS Current Price shows “Buy” Signal.
Array BioPharma Inc. (NASDAQ:ARRY) gained 3.38 Percent and closed its previous trading session at $17.15. The stock traded with the average Volume of 4.03 Million at the end of last session.
Array BioPharma Inc. (NASDAQ:ARRY) has the Market Capitalization of 3.35 Billion. The Stock has its 52-week High of $18.24 and 52-Week Low of $ 6.73 and it touched its 52-week high on 02/08/18 and 52-Week Low on 05/09/17.
The company reported its last earnings Actual EPS of $-0.17/share. While, the analyst predicted that the company could provide an EPS of $-0.23/share. Hence the difference between Predicted EPS and Actual EPS reported is $0.06/share which shows an Earnings Surprise of 26.1 Percent.
Sell side analysts plays vital role in buying and selling a stock where 1 analysts rated Array BioPharma Inc. (NASDAQ:ARRY) as Buy, 0 analysts given Outperform signal, 0 reported Hold, and 0 analysts rated the stock as Sell.
The stock’s current distance from 20-Day Simple Moving Average (SMA20) is 12.36% where SMA50 and SMA200 are 28.47% and 63.69% respectively.
The company shows its Return on Assets (ROA) value of -36.5%. The Return on Equity (ROE) value stands at -107.8%. While it’s Return on Investment (ROI) value is -71.1%.
Array BioPharma Inc. (NASDAQ:ARRY) currently has a Weekly Volatility of 6.77% percent while its Monthly Volatility is at 6.93% percent. While talking about Performance of the Stock, Array BioPharma Inc. currently has a Weekly performance of -2.28%, monthly performance percentage is 32.23 percent, Quarterly performance is 61.64 percent, 6 months performance shows a percent value of 91.83% and Yearly Performance is 42.92 percent.
Array BioPharma Inc. is a biopharmaceutical company focused on the discovery, development and commercialization of targeted small molecule drugs to treat life threatening and debilitating diseases. The company’s proprietary drug development pipeline is focused on the treatment of cancer and inflammatory disease and includes clinical candidates that are designed to regulate therapeutically important targets. In addition, leading pharmaceutical and biotechnology companies collaborate with Array to discover and develop drug candidates across a broad range of therapeutic areas.